Euro vs US Dollar

Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

Registrieren

DTIL Precision BioSciences Inc

4,72

-0,36 (-7,09%)

Vor Marktöffnung

Zuletzt aktualisiert: 13:30:17

Verzögert um 15 Minuten

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Click Here for more Precision BioSciences Charts.

Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
Von Jan 2024 bis Jan 2025

Click Here for more Precision BioSciences Charts.

News Precision BioSciences Inc

Form 144 - Report of proposed sale of securities
Freitag 24 Januar 2025 (3 Tage vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 23 Januar 2025 (4 Tage vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 23 Januar 2025 (4 Tage vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 23 Januar 2025 (4 Tage vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 23 Januar 2025 (4 Tage vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mittwoch 22 Januar 2025 (5 Tage vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mittwoch 22 Januar 2025 (5 Tage vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Dienstag 21 Januar 2025 (6 Tage vor) • Edgar (US Regulatory)

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
Donnerstag 9 Januar 2025 (3 Wochen vor) • Business Wire

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
Donnerstag 9 Januar 2025 (3 Wochen vor) • Business Wire

Form 8-K - Current report
Mittwoch 8 Januar 2025 (3 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 2 Januar 2025 (4 Wochen vor) • Edgar (US Regulatory)

Weitere Precision BioSciences Inc News-Artikel

Health Care Select Sector

Deutsche Lufthansa

JP Morgan Chase

Euro vs Sterling

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen